Prevalence and Impact of Minority Variant Drug Resistance Mutations in Primary HIV-1 Infection

Joanne D. Stekler1,3*, Giovanina M. Ellis4, Jacquelyn Carlsson4, Braiden Eilers1, Sarah Holte3,5, Janine Maenza1, Claire E. Stevens1, Ann C. Collier1,3, Lisa M. Frenkel2,3,5

1 Department of Medicine, University of Washington, Seattle, Washington, United States of America, 2 Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America, 3 Center for AIDS and STDs, University of Washington, Seattle, Washington, United States of America, 4 Seattle Children’s Hospital and Research Institute, Seattle, Washington, United States of America, 5 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

Abstract

Objective: To evaluate minority variant drug resistance mutations detected by the oligonucleotide ligation assay (OLA) but not consensus sequencing among subjects with primary HIV-1 infection.

Design/Methods: Observational, longitudinal cohort study. Consensus sequencing and OLA were performed on the first available specimens from 99 subjects enrolled after 1996. Survival analyses, adjusted for HIV-1 RNA levels at the start of antiretroviral (ARV) therapy, evaluated the time to virologic suppression (HIV-1 RNA<50 copies/mL) among subjects with minority variants conferring intermediate or high-level resistance.

Results: Consensus sequencing and OLA detected resistance mutations in 5% and 27% of subjects, respectively, in specimens obtained a median of 30 days after infection. Median time to virologic suppression was 110 (IQR 62–147) days for 63 treated subjects without detectable mutations, 84 (IQR 56–109) days for ten subjects with minority variant mutations treated with ≥3 active ARVs, and 104 (IQR 60–162) days for nine subjects with minority variant mutations treated with <3 active ARVs (p = .9). Compared to subjects without mutations, time to virologic suppression was similar for subjects with minority variant mutations treated with ≥3 active ARVs (aHR 1.2, 95% CI 0.6–2.4, p = .6) and subjects with minority variant mutations treated with <3 active ARVs (aHR 1.0, 95% CI 0.4–2.4, p = .9). Two subjects with drug resistance and two subjects without detectable resistance experienced virologic failure.

Conclusions: Consensus sequencing significantly underestimated the prevalence of drug resistance mutations in ARV-naive subjects with primary HIV-1 infection. Minority variants were not associated with impaired ARV response, possibly due to the small sample size. It is also possible that, with highly-potent ARVs, minority variant mutations may be relevant only at certain critical codons.

Introduction

Transmission of drug resistant HIV-1 has been well-documented following the widespread availability of antiretroviral (ARV) therapy [1–11]. In the United States, cross-sectional surveys using consensus sequencing estimate that 11–24% of persons acquire drug resistant HIV-1 [8,9,12,13]. National guidelines therefore recommend genotypic resistance testing for ARV-naive persons at entry into care [14].

Consensus sequencing cannot consistently detect viral variants unless they comprise greater than 10–50% of the population [15–20], and studies using more-sensitive assays have detected mutations at lower concentrations (i.e. “minority variant” mutations) in up to half of ARV-naive subjects [21–24]. However, the impact of minority variants on HIV-1 disease progression and response to ARVs remains unclear. Some studies have found associations between minority variant mutations and poor clinical outcomes [23–30] or that outcomes were dependent on the specific mutant codon and ARV therapy used [23,30,31], but others have found no association between minority variants and treatment responses [32–34].

The oligonucleotide ligation assay (OLA) is an HIV-1 drug resistance assay that is more sensitive than consensus sequencing and can detect mutations at select codons when they occur in as few as 2–5% of the viral quasi-species [35–38]. This study evaluated the prevalence of mutations detected by OLA and the impact of minority variants on responses to ARV therapy in a cohort of subjects with primary HIV-1 infection.

Materials and Methods

Patient population

Characteristics of the University of Washington Primary Infection Clinic (PIC) cohort have previously been described...
or sequencing and OLA. We preferentially selected subjects who 1) had enrolled in the cohort within one month of their estimated date of HIV-1 infection (defined as the date of onset of seroconversion symptoms or, for asymptomatic individuals, the midpoint between dates of the last negative and first positive HIV-1 tests), 2) had results of a pretreatment HIV-1 drug resistance test (consensus sequencing) already available, and/or 3) initiated ARV therapy within six months of study enrollment. We performed consensus sequencing and sensitive drug resistance testing to determine HIV-1 genotype on the first available (i.e. baseline) plasma and peripheral blood mononuclear cell (PBMC) specimens that had been collected no more than seven days after the start of ARVs. Thirty-four subjects had consensus sequencing performed as part of clinical research evaluations prior to our undertaking this analysis; results of resistance testing performed specifically for this study were not used to guide selection of ARV therapy. This study was approved by the University of Washington Institutional Review Board, and all subjects gave written consent for participation in the cohort.

**HIV-1 RNA quantification in blood plasma**

Specimens collected between 1996 and 2002 were initially tested with branched DNA (bDNA) assays with lower limits of detection of 50 and 500 copies/mL (Chiron Corporation; Emeryville, CA). When specimens were available, results censored at 500 copies/mL were re-tested using an ultra-sensitive reverse transcription polymerase chain reaction (RT-PCR) assay (Roche; Branchburg, NJ) or an independently-validated real-time RT-PCR amplification assay with lower limits of detection equal to 50 copies/mL [42]. Since 2002, all specimens have been evaluated by an RT-PCR assay.

**RT-PCR and PCR for genotyping of HIV-1 pol**

RNA was extracted from plasma and reverse transcribed, as previously described [35]. DNA was extracted from PBMCs using the PureGene Cell and Tissue kit (Gentra Systems, Inc.; Minneapolis, MN) according to manufacturers’ instructions. Nested PCR was performed as previously described [37] with different primers. Briefly, first-round PCR of cDNA or DNA was carried out in a 50-μl reaction mixture containing 10-μl of cDNA or ≥1 μg DNA, and second-round PCR contained 2-μl of the first-round product. First round primers were PRA and RTA; second round primers were PRB and RT3 [43]. If no amplicon was produced, we used alternate primer sets NE10 and NE11. We visualized the amplicon, a 1,193-bp DNA fragment extending from amino acid 1 in protease to amino acid 230 in reverse transcriptase, in 1% agarose gel with ethidium bromide staining. Samples with a visible band of the correct size were used for sequencing and OLA.

**Consensus sequencing**

PCR amplicons were purified and sequenced as previously described [37] using sequencing primers that were identical to those used for second-round PCR. Sequences were analyzed with Sequencher, version 4.2 (Gene Codes Corp; Ann Arbor, MI), and submitted to the Stanford HIV-1 Sequence Analysis Program [44] to identify mutations. For quality assurance, all genotypes generated for this study were aligned with ClustalW, v1.81 and reviewed using a neighbor-joining phylogenetic tree to monitor for cross-contamination.

**Statistical analysis**

We used McNemar’s exact tests to compare the number of subjects with transmitted drug resistance mutations detected by OLA and consensus sequencing of plasma, by OLA and consensus sequencing of PBMCs, and by OLA of plasma to OLA of PBMCs. Multivariable regression models explored factors potentially associated with risk of transmitted drug resistance and included year of HIV-1 acquisition (divided into quartiles) to evaluate for evidence of a secular trend.

We used 2-sample t-tests, non-parametric tests, and regression analyses where appropriate to compare mean baseline (i.e. first visit) CD4 + T-cell count, baseline HIV-1 RNA level, and median viral “set point” among subjects with minority variant mutations and subjects without detectable transmitted drug resistance. We estimated set point using the HIV-1 RNA level obtained closest to 150 days (between 120 and 730 days) following HIV-1 infection from subjects who had not yet received ARV therapy [45].

We conducted time-to-event analyses using Cox proportional hazard regression models with maximum likelihood estimation to compare time to virologic suppression (defined as the first HIV-1 RNA below 50 copies/mL) among subjects receiving highly active antiretroviral therapy. These analyses were adjusted for pretreatment HIV-1 RNA level closest to and within 30 days before the start of ARVs. We excluded subjects from the time-to-event analyses if they received only single or dual nucleoside reverse transcriptase inhibitor (NRTI) therapy or if they had any mutations detected by consensus sequencing because pre-treatment resistance testing could have guided selection of ARVs. The Stanford University HIV Drug Resistance Database (http://hivdb.stanford.edu; accessed December 29, 2009) was used to predict the number of active agents in regimens; an ARV agent was considered inactive if subjects had a mutation associated with intermediate or high-level HIV-1 drug resistance to that ARV. Subjects were divided into three groups: 1) subjects without any HIV-1 drug resistance mutations detected by consensus sequencing or OLA, 2) subjects with minority variant mutations treated with ARV regimens with three or more active ARV agents, and 3) subjects with minority variant mutations treated with ARV regimens with fewer than three active agents. Virologic failure was defined as: 1) failure to suppress HIV-1 RNA levels to below 50 copies/mL within 240 days after initiation of ARVs, 2) switch of ARV agents due to a perceived inadequate response to therapy, or 3) viral rebound to greater than 500 copies/mL on two consecutive measurements following successful suppression of HIV-1 RNA levels to below 50 copies/mL. All statistical analyses were performed using Stata9 software (StataCorp LP, College Station, TX).
Results

Demographics and other baseline characteristics of the 99 subjects are shown in Table 1. All subjects were men, and 98% of subjects reported sex with men as their risk for HIV-1 acquisition. Subjects who experienced symptoms consistent with the acute retroviral syndrome (92%) were over-represented in this analysis compared to the entire PIC cohort (84%). All subjects acquired HIV-1 subtype B infection.

We performed HIV-1 drug resistance testing on plasma and PBMC specimens that had been obtained a median of 29 [IQR 19–66] and 31 [IQR 19–66] days after HIV-1 infection; all specimens were collected within six months of infection. Consensus sequencing and OLA detected HIV-1 drug resistance mutations in plasma or PBMCs specimens in 5% and 27% of 99 subjects, respectively. There was no evidence of a trend in incidence of transmitted drug resistance over time, although resistance was more common among subjects infected after May 2000 (31%) compared to those infected prior to this date (16%), and we did not detect non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance among subjects infected prior to this date.

Compared to consensus sequencing, OLA detected significantly greater number of subjects with resistance mutations in both plasma (p = .0005) and PBMCs (p = .002) (Table 2). OLA performed on plasma and PBMCs detected similar numbers of subjects with drug resistance mutations, but concordance of results was low.

Consensus sequencing detected one subject with M184V in PBMCs only, one subject with M1L4L and T215D, one subject with T215D and L90M, and two subjects with G190A. The mutations most commonly identified by OLA in reverse transcriptase were M184V (n = 9) and T215Y (n = 5) and in protease were I84V (n = 5) and N88D (n = 5). K103N was identified in only one subject and by OLA only. With use of OLA, detection of NNRTI resistance mutations increased from 3% to 13% of subjects, detection of NNRTI resistance mutations increased from 2% to 8% of subjects, detection of protease inhibitor (PI) resistance mutations increased from 1% to 13% of subjects, and detection of multi-drug resistant HIV-1 increased from 1% to 6% of subjects.

Compared to subjects without detectable mutations, there were no differences in the CD4+ T-cell counts or HIV-1 RNA levels at presentation among subjects having at least one mutation detected by OLA or subjects with mutations conferring resistance to NRTIs, NNRTIs, or PIs. Among 24 subjects in this study who remained untreated at a median of 146 days following HIV-1 infection, the median viral “set point” was 4.5 (IQR 3.7–4.8) log_{10} copies/mL among five subjects with minority variant mutations and 4.5 (IQR 4.1–5.3) log_{10} copies/mL among 19 subjects with no detectable drug resistance mutations (p = .6).

Eighty-nine (90%) of the 99 subjects initiated ARV therapy a median of 48 [IQR 24–107, range 5–1092] days after HIV-1 infection (Table 3). Mean CD4+ T-cell counts (498 versus 486 cells/mm³, p = .8) and HIV-1 RNA levels (5.1 versus 4.9 log_{10} copies/mL, p = .5) at the start of ARV therapy did not differ between subjects without detectable mutations and those with minority variant mutations. Similarly, we found no association between any class of drug resistance mutation and CD4 count or HIV-1 RNA level at the start of ARV therapy.

The five subjects with mutations detected by consensus sequencing and two other treated subjects without follow-up were excluded from survival analyses. Median time to HIV-1 RNA less than 50 copies/mL was 110 [IQR 62–147] days for 63 treated subjects without detectable mutations, 84 [IQR 56–109] days for ten subjects with minority variant mutations treated with three or more active ARVs, and 104 [IQR 60–162] days for nine subjects with minority variant mutations treated with fewer than three active ARVs (p = .9) (Figure 1). After adjustment for HIV-1 RNA levels at the start of ARV therapy, time to virologic suppression was similar (aHR 1.2, 95% CI 0.6–2.4, p = .6) for subjects with minority variant mutations treated with at least three active agents and for subjects with minority variant drug resistance mutations who received fewer than three active ARV agents (aHR 1.0, 95% CI 0.4–2.4, p = .9) compared to subjects without drug resistance mutations.

Table 1. Characteristics of study subjects with primary HIV-1 infection evaluated for drug resistance mutations.

| No mutations | Mutations by OLA only | Mutations by CS | All Subjects |
|--------------|----------------------|----------------|-------------|
| n = 72       | n = 22               | n = 5          | n = 99      |
| Age (median, IQR) | 34 (30–38)          | 37 (30–43)      | 33 (33–41)   | 34 (30–40) | NS |
| Caucasian, non-Hispanic | 92%               | 95%            | 100%         | 93%         | NS |
| Days from infection to screening (median, IQR) | 22 (13–52)       | 32 (24–63)     | 54 (34–80)   | 27 (15–63) | p = .05 |
| CD4+ T-cell count at first visit (median cells/mm³, IQR) | 494 (386–678) | 551 (394–700)  | 421 (396–550) | 496 (392–694) | NS* |
| HIV RNA level at first visit (median log_{10} copies/mL, IQR) | 5.4 (4.5–6.2) | 5.1 (4.6–5.5)  | 5.2 (5.0–6.0) | 5.2 (4.5–6.0) | NS* |
| Median date of HIV infection (IQR) | 8/01 (1/00–1/04) | 4/02 (4/01–1/04) | 1/02 (8/00–4/04) | 11/01 (4/00–2/04) | NS |
| Received ARV treatment | 64 (89%)        | 20 (91%)       | 5 (100%)    | 89 (90%)    | NS |
| PI/NRTI | 26 (41%)          | 7 (35%)        | 2 (40%)     | 35 (39%)    | NS |
| Initial NRTI / NRTI | 24 (38%)        | 9 (45%)        | 2 (40%)     | 35 (39%)    | NS |
| ARV PI/NRTI/NRTI | 13 (20%)        | 3 (15%)        | 1 (20%)     | 17 (19%)    | |
| regimen NRTI only | 1 (2%)          | 1 (5%)         | 0           | 2 (2%)      | |

OLA: oligonucleotide ligation assay; CS: consensus sequencing; IQR: interquartile range; NS: not significant at p = .05; ARV: antiretroviral; PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor therapy.

* Differences between groups were not significant in analyses that were both unadjusted and adjusted for time from infection to the date of sampling.

doi:10.1371/journal.pone.0028952.t001
The eighty-seven treated subjects, including the five subjects with mutations identified by consensus sequencing, were followed for a median of 4.4 (IQR 2.6–7.7) person-years following the start of ARV therapy. Only four (5%) subjects experienced virologic failure. One subject (Table 3 ID #95816) did not have resistance testing performed prior to starting ARV therapy. After virologic failure, G190A was identified in his baseline specimen by both consensus sequencing and OLA. The second subject with virologic failure (ID #26973) had no major mutations identified by consensus sequencing. His HIV-1 RNA level decreased to 2.0 \( \log_{10} \) copies/mL before it quickly rebounded; T215Y was detected by only OLA in his PBMCs from baseline. Drug resistance mutations were not identified at baseline in two other subjects who experienced virologic failure after receiving ARV therapy for five months and five years;

**Discussion**

The results described here represent one of the most comprehensive surveys of minority variant drug resistance in primary HIV-1 infection in terms of the number of mutations studied. We detected drug resistance mutations in 27% of a male cohort who acquired HIV-1 infection after 1996. Despite a high prevalence of minority variant drug resistance mutations, this was not associated with a difference in viral set point or in the virologic response to ARV therapy among treated subjects.

The finding that a sensitive assay detected HIV-1 drug resistance mutations in a greater number of subjects compared to consensus sequencing is consistent with other studies of ARV-naive subjects with primary HIV-1 infection [21,32] and established HIV-1 infection [24,46]. Although the high prevalence of minority variants in our subjects is somewhat congruous with the previously-held belief that sexual transmission of HIV infection is predominantly monophyletic, more recent data have suggested that men who have sex with men frequently acquire multiple variants [47]. It is also possible that OLA detected variants that had been spontaneously generated by random misincorporation of base pairs during reverse transcription of HIV RNA. However, although possible, it is unlikely that, without ARV selection pressure, mutations could be generated with sufficient frequency to reach a level detectable by OLA in nearly one quarter of our subjects [48]. It is also conceivable that false positive results contributed to the estimated prevalence of drug resistance in our subjects. Although ligase binding is highly specific [49], false positive results could have occurred due to high background in the EIA portion of the assay for isolated specimens.

In contrast to our previous study of ARV-experienced persons with chronic HIV-1 infection [37], OLA of PBMC DNA did not detect a greater number of persons with mutations compared to OLA of plasma RNA. All minority variant drug resistance mutations detected in this study were identified in only one component of blood (i.e. either plasma or PBMCs but not both). These specimens had concentrations of mutant virus that were close to the limit of detection of the assay, and thus detection in plasma or PBMCs was likely stochastic. We suspect that the reason the numbers of persons who had mutations detected in one component or the other were similar was due to detection of specimens during primary infection with insufficient time lapse for wild-type viruses to have overgrown less fit mutants in plasma, where virus turnover occurs more rapidly. One of the strengths of this work is that we studied subjects close to the time of HIV acquisition, as outgrowth of some wild-type viruses can occur very quickly [50,51]. We also cannot exclude the possibility that minority variants were spontaneously generated, as mentioned above.

Similar to other studies [32–34], we found that low-level mutations did not appear to affect the time to virologic suppression following initiation of ARV therapy in treated subjects. In contrast, studies of persons with established HIV-1 infection have shown an increased risk of virologic failure associated with minority variant drug resistance mutations [23,24,26,27,29,30], particularly with NNRTI mutations [28–31]. The high rate of treatment success among our subjects was similar to another observational study of subjects with primary HIV-1 infection [52], but as a result only 4% of subjects were observed to have virologic failure and our study was underpowered to detect differences in clinical outcomes. Although the median follow-up time in our study was longer than other studies that observed higher rates of virologic failure, it is possible we would have seen differences in rates of virologic failure if subjects had remained on treatment and in follow-up or if we had studied more subjects.

Another likely explanation for our failure to identify negative consequences from minority variant mutations was the lack of uniformity of the impact of HIV-1 drug resistance mutations across regimens and the use of ARV therapy with a high genetic barrier to resistance to the mutations we observed. Much prior research on this topic has focused on NNRTI mutations, which have a lower genetic barrier to resistance. Of the two subjects in our cohort with NNRTI mutations who were treated with NNRTI-based regimens, the one who had high concentrations of mutant experienced virologic failure (ID#95816). The second subject (ID#44378) had the Y181C mutation detected only by
OLA; he was treated with nevirapine and had an initial $3 \log_{10}$ copies/mL decrease in his HIV-1 RNA level, but he discontinued medications after forty-four days due to rash. It is possible that the clinical impact of minority variant drug resistance mutations may be modified by the relative concentration of the mutant virus at specific codons [23,30,53]. In one recent study, subjects who had NNRTI resistance mutations detected in 1–20% of the viral population had a lower risk of virologic failure following initiation of ARV therapy compared to subjects who had NNRTI resistance mutations detected in greater than 20% of the population, but both groups had a greater risk of virologic failure compared to subjects who did not have NNRTI resistance mutations [23]. These authors did not observe a similar relationship between risk of virologic failure and variation in concentrations of NRTI or PI mutations. Another recent study suggested that the K103N mutation was associated with an increased risk of virologic failure when these viruses were present in amounts greater than 2000 copies/mL [54]. However, like many previously published studies, we did not quantify the amount of virus used for drug resistance assays and therefore cannot report the precise concentrations of minority variants that were detected.

### Table 3. HIV-1 drug resistance detected by consensus sequencing and OLA in ARV-naive subjects and virologic response to ARV therapy.

| Group | ID     | Infection Year | CS (plasma) | CS (PBMC) | OLA (plasma) | OLA (PBMC) | VL at ARV start$^1$ | Initial ARVs | #Active ARVs | Time to VL<50 (days) | VF  |
|-------|--------|----------------|-------------|-----------|--------------|-------------|---------------------|--------------|--------------|----------------------|-----|
| I     | 95816  | 2000           | G190A       | G190A     | G190A        | G190A       | 4.9                 | ABC, 3TC, EFV | RTV-APV→ABC, 3TC, NVP | 4→2$^2$     | 57     | yes    |
|       | 69234  | 2004           | G190A       | G190A     | G190A        | M184V, T215Y, G190A | 5.6                 | AZT, 3TC, 3r-LPV    | 1           | 87$^3$    |         |
| I     | 43999  | 2002           | M184V       | M184V     |              |             | 4                   | ABC, 3TC, EFV | 2           | 27             |     |
|       | 56710  | 1999           | M41L, T215D | M41L, T215D | T215Y$^4$   |             | 4.5                 | 3TC, d4T, IDV, HU  | 2           | 176             |     |
|       | 35188  | 2004           | T215D, L90M | T215D, L90M | L90M$^4$   | L90M$^4$   | 5.4                 | TDF, FTC, EFV | 3           | 216             |     |
|       | 34993  | 2000           | V82A        |           | V82A         |             | 4.1                 | ABC, 3TC, IDV, EFV | 3           | 15              |     |
|       | 41319  | 2002           | I84V, N88D  |           |              |             | 4.2                 | ABC, 3TC, EFV | 3           | 55              |     |
|       | 19198  | 2003           | Y181C, I84V |           |              |             | 5.4                 | AZT, 3TC, r-LPV    | 3           | 56              |     |
| II    | 83622  | 2000           | M184V       |           |              |             | 5.3                 | ABC, 3TC, IDV, EFV | 3           | 60              |     |
|       | 35057  | 2004           | I84V        |           |              |             | 5                   | ABC, 3TC, EFV | 3           | 84              |     |
|       | 18309  | 2003           | N88D        | D30N      |              |             | 5.4                 | ABC, 3TC, EFV | 3           | 85              |     |
|       | 44375  | 2003           | N88D        |           |              |             | 4.5                 | ABC, 3TC, r-IDV    | 3           | 104             |     |
|       | 66121  | 2001           | 150V        | N88D      |              |             | 4.5                 | ABC, 3TC, EFV | 3           | 109             |     |
|       | 28477  | 2005           | K103N       |           |              |             | 4.3                 | TDF, FTC, r-LPV    | 3           | 181             |     |
|       | 50047  | 2004           | I84V        |           |              |             | 4.8                 | ABC, 3TC, EFV | 3           | 266             |     |
|       | 78056  | 2003           | I84V        |           |              |             | 4.1                 | ABC, 3TC, r-IDV    | 2           | 55              |     |
|       | 97929  | 2001           | M184V       |           |              |             | 4.5                 | ABC, 3TC, EFV | 2           | 60              |     |
|       | 71670  | 2000           | M184V, Y181C|           |              |             | 4.5                 | ABC, 3TC, IDV, EFV | 2           | 84              |     |
|       | 85163  | 2001           | M184V       |           |              |             | 4.9                 | ABC, 3TC, r-IDV    | 2           | 104             |     |
| III   | 53754  | 2000           | M184V, N88D |           |              |             | 4.8                 | 3TC, d4T, NVP       | 2           | 162             |     |
|       | 49635  | 2001           | M184V, Y181C|           |              |             | 4.7                 | ABC, 3TC, r-IDV    | 2           | 165             |     |
|       | 26973  | 2002           | T215Y       |           |              |             | 5                   | ABC, AZT, 3TC     | 2           | DNS$^5$ yes     |     |
|       | 44378  | 2005           | Y181C       |           |              |             | 5.9                 | AZT, 3TC, NVP      | 2           | DNS$^5$         |     |
|       | 78882  | 2004           | K65R, M184V,T215Y, I50V |   |              |             | 5.3                 | TDF, FTC, r-ATZ    | 1           | DNS$^5$         |     |

In this table, the subset of subjects who received antiretroviral (ARV) therapy are grouped based on whether they had drug resistance detected by consensus sequencing (Group I), drug resistance detected by OLA but who received at least three active ARV agents (Group II), or drug resistance detected by OLA who received fewer than three active agents (Group III). ARVs are highlighted in grey if subjects had mutations conferring at least intermediate level resistance to that ARV. K70R, L74V, T215F, and V82S/T were not detected in any treated subjects. CS: consensus sequencing; OLA: oligonucleotide ligation assay; VL: viral load (HIV-1 RNA level); ARV: antiretroviral; VF: virologic failure; IDV: indinavir, HU: hydroxyurea, ABC: abacavir, EFV: efavirenz, NVP: nevirapine, r: ritonavir-boosted, LPV: lopinavir, ATZ: atazanavir; DNS: did not suppress.

$^1$Log$_{10}$ copies/mL.

$^2$Antiretroviral medications were switched on day 5 due to side effects.

$^3$Subject #69234 subsequently discontinued medications two months later due to adherence difficulties.

$^4$OLA probes did not test for M41L and T215D.

$^5$OLA on PBMC for subject 56710 yielded indeterminate results for T215Y.

$^6$DNS: did not suppress prior to discontinuing ARVs or study censorship. Subjects #26973, 44378, and 78882 were followed for 104, 44, and 63 days, respectively, while receiving ARVs.

doi:10.1371/journal.pone.0028952.t003

OLA; he was treated with nevirapine and had an initial $>3 \log_{10}$ copies/mL decrease in his HIV-1 RNA level, but he discontinued medications after forty-four days due to rash. It is possible that the clinical impact of minority variant drug resistance mutations may be modified by the relative concentration of the mutant virus at specific codons [23,30,53]. In one recent study, subjects who had NNRTI resistance mutations detected in 1–20% of the viral population had a lower risk of virologic failure following initiation of ARV therapy compared to subjects who had NNRTI resistance mutations detected in greater than 20% of the population, but both groups had a greater risk of virologic failure compared to subjects who did not have NNRTI resistance mutations [23]. These authors did not observe a similar relationship between risk of virologic failure and variation in concentrations of NRTI or PI mutations. Another recent study suggested that the K103N mutation was associated with an increased risk of virologic failure when these viruses were present in amounts greater than 2000 copies/mL [54]. However, like many previously published studies, we did not quantify the amount of virus used for drug resistance assays and therefore cannot report the precise concentrations of minority variants that were detected.
It is also possible that the clinical impact of minority variant transmitted drug resistance mutations may be further modified by the persistence or decay in concentration of the mutant virus. In several studies, receipt of single dose nevirapine (SD-NVP) has been associated with poor subsequent response to NVP-based ARV therapy when treatment was initiated within six months of the SD-NVP [53,56]. It is plausible that the interaction between delayed initiation of ARV therapy following SD-NVP and reduced risk of virologic failure is mediated by decay in the concentration of HIV-1 drug resistant variants over time. In the study by Jourdain et al. [56], risk for virologic failure was associated with detection of mutations by OLA at the time of initiation of ARVs but not with detection of mutations by consensus sequencing ten days post-partum. How the specific mutations, threshold levels, dynamics of decay, and timing and type of ARV therapy all interact to modify the effect of transmitted drug resistance remains to be determined. A longitudinal study is ongoing that will quantify minority variants over time in a greater number of subjects with primary HIV-1 infection.

Although OLA is more sensitive than consensus sequencing, more sensitive assays such as allele-specific PCR [57,58] and parallel allele-specific sequencing (PASS) [59] can detect HIV-1 drug resistance mutations in as little as 0.01–1% of the viral population if sufficient numbers of viruses are studied. Had we used one of these assays, it is possible that we would have estimated that the prevalence of HIV-1 drug resistance was even greater, and we might have found a relationship between drug resistance and virologic response to therapy. However, in our hands, OLA and pyrosequencing produce similar results when mutant viruses are at concentrations greater than 2% of the viral population [60], and the clinical relevance of minority variants at even lower concentrations is even less clear. At the highest sensitivity, it is possible to detect and misclassify random mutations, as some mutations were detected among HIV-infected persons even prior to the availability of ARVs [48,61]. Advantages of OLA include the greater specificity compared to PCR-based methods [62], reagents anneal at relatively low temperature (37°C) and therefore tolerate polymorphisms in the region of the probe, OLA uses relatively less costly equipment than allele-specific PCR and pyrosequencing, and oligonucleotides have been adapted to non-B subtypes [63].

In conclusion, results from this study reinforce findings of others that consensus sequencing significantly underestimates the point prevalence and possibly the “persistence” of transmitted HIV-1 drug resistance mutations. However, additional data are still needed to precisely determine the clinical impact of different drug resistance mutations at different concentrations. If minority variants are clinically important, use of more-sensitive assays might aid in the selection of potent ARV regimens with greatest chance of success. On the other hand, if minority variant drug resistance mutations have minimal clinical impact in ARV-naive individuals, the detection of minority variants might lead care providers to prescribe complex first-line ARV regimens with a high pill burden and frequent dosing. Higher complexity of ARV regimens could reduce patient adherence and lead to a paradoxical increase in the prevalence of drug resistance. Given the uncertainty regarding the clinical impact of minority variant mutations and the fact that many people with these mutations still have excellent responses to therapy, prospective randomized trials that include cost-effectiveness analyses should be completed prior to the adoption of more-sensitive assays for clinical care.

Acknowledgments

We would like to thank the subjects who participated in this cohort, Terri Smith and Caitlin Burgess for data and statistical support, and our many past and current collaborators in the Seattle Primary Infection Program. Presented in part at the 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; February 8–11, 2009 [abstract #674].

Author Contributions

Conceived and designed the experiments: JDS GME ACC LMF. Performed the experiments: GME JC BE. Analyzed the data: JDS GME JC BE SH ACC LMF. Contributed reagents/materials/analysis tools: JDS SH LMF. Wrote the paper: JDS GME JC BE SH JM CES ACC LMF. Performed clinical evaluations of the cohort: JDS JM CES ACC.
References

1. Little SJ, Daar ES, D’Aquila RT, Keiffer PH, Connick E, et al. (1999) Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282: 11-14.

2. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, et al. (1998) Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N Engl J Med 339: 307-311.

3. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, et al. (1999) Transmission of antiretroviral-resistant HIV-1 variants. Lancet 354: 729-733.

4. Salomon H, Wainberg MA, Brenner B, Qun Y, Rouleau D, et al. (2000) Prevalence of HIV-1 resistance to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14: F17-23.

5. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, et al. (1999) HIV-1 drug resistance in newly infected individuals. JAMA 282: 1153-1161.

6. Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, et al. (1993) Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 302: 1067-1068.

7. Metzner KJ, Allers K, Rauch P, Harrer T (2007) Rapid selection of drug-resistant HIV-1 variants in antiretroviral treatment-naive patients and their impact on the virological failure. J Clin Virol 43: 34-38.

8. Van Lathem K, De Munter P, Schooten Y, Verbree B, Van Ranst M, et al. (2007) No response to first-line tenofovir/lamivudine/efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol 39: 43-47.

9. Metzner KJ, Guitierrez KG, Knoepfel SA, Rauch P, Burgisser P, et al. (2009) Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 48: 239-247.

10. Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, et al. (2009) Low frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy, J Acquir Immune Defic Syndr 52: 569-573.

11. Halvors EK, Wierand A, Boltz VF, Kearnery M, Nisley D, et al. (2011) Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 201: 672-680.

12. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, ShakaMA, et al. (2010) Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 201: 662-671.

13. Li JZ, Paredes R, Ribaudo HJ, Svaroskaia ES, Metzner KJ, et al. (2011) Low frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305: 1327-1335.

14. Peuchant O, Thiebaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, et al. (2008) Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 22: 1417-1423.

15. Jakobsen MR, Tolstrup M, Boller J, Jorgensen LR, Berry PR, et al. (2010) Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. J Infect Dis 50: 566-573.

16. Metzner KJ, Rauch P, von Wyl V, Leman G, Grebe C, et al. (2010) Efficient suppression of minority drug-resistant HIV-1 subtype B HIV-1 variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 201: 1063-1071.

17. Edelstein RE, Nickerson DA, Toby VO, Mann-Nonouac LA, Frenkel LM (1998) Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol 36: 569-572.

18. Berlin IA, Mahalalabits M, Pepper G, Wright A, Hamilton S, et al. (2002) Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol 40: 1413-1419.

19. Ellefsen LM, Berlin IA, Parker G, Wright A, et al. (2004) Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol 42: 3670-3674.

20. Meek MA, Blanco AJ, Beck IA, Dross S, Matunha L, et al. (2010) Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis 80: 1405-1414.

21. Schacker T, Collier AC, Hughes J, Shek T, Corey L. (1996) Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 125: 257-264.

22. Salomon H, Wainberg MA, Brenner B, Qun Y, Rouleau D, et al. (2000) Prevalence of drug-resistant variants of human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol 36: 569-572.

23. Berlin IA, Mahalalabits M, Pepper G, Wright A, Hamilton S, et al. (2002) Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol 40: 1413-1419.

24. Ellefsen LM, Berlin IA, Parker G, Wright A, et al. (2004) Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol 42: 3670-3674.

25. Meek MA, Blanco AJ, Beck IA, Dross S, Matunha L, et al. (2010) Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis 80: 1405-1414.

26. Schacker T, Collier AC, Hughes J, Shek T, Corey L. (1996) Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 125: 257-264.

27. Barrey MM, Schacker T, Collier AC, Shea T, Brodie SJ, et al. (2001) Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 183: 1466-1475.

28. Stiegl T, Holte S, Maenza J, Stevens CE, Collier AC. Clinical outcomes of antiretroviral treatment initiated during primary HIV infection [j946]. February 25-28, Los Angeles, CA.

29. Li CG, Seidel KD, Coombs RW, Frenkel LM (2005) Detection and quantification of human immunodeficiency virus type 1 pol proviral DNA in dried whole blood and plasma on filter paper stored under various conditions. J Clin Microbiol 43: 3901-3905.

30. Genotyping kits for the detection of HIV-1 pol drug resistance mutations by an oligonucleotide ligation assay. Protocol version 4.1, July 2007. Seattle Children’s Hospital Research Institute, February 2008. Available at http://drpts.washington.edu/idmmsweb/facultyMember.php?agent=Frenkel.

31. Stanford University HIV Drug Resistance Database, http://hivdb.stanford.edu/pages/algos/HIVdb.html, accessed July 17, 2007.

32. Mei Y, Wang L, Holte SE (2008) A comparison of methods for determining HIV drug resistance. J Acquir Immune Defic Syndr 49: e1000890.

33. Ellis GM, Mahalanabis D, Beck IA, Parker G, Wright A, et al. (2004) Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol 42: 3670-3674.

34. Metzner KJ, Rauch P, von Wyl V, Leman G, Grebe C, et al. (2010) Efficient suppression of minority drug-resistant HIV-1 subtype B HIV-1 variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 201: 1063-1071.

35. Edelstein RE, Nickerson DA, Toby VO, Mann-Nonouac LA, Frenkel LM (1998) Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol 36: 569-572.

36. Berlin IA, Mahalalabits M, Pepper G, Wright A, Hamilton S, et al. (2002) Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol 40: 1413-1419.

37. Ellis GM, Mahalanabis D, Beck IA, Parker G, Wright A, et al. (2004) Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol 42: 3670-3674.
50. Barbour JD, Hecht FM, Win T, Liegler TJ, Ramstead CA, et al. (2004) Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18: 1683–1689.
51. Jain V, Sacquira MC, Bucchetti P, Hartogensis W, Diaz RS, et al. (2011) Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 203: 1174–1181.
52. Kassuto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, et al. (2006) Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 42: 1024–1031.
53. Goodman D, Margo N, MCColl D (2009) Pre-existing low-levels of the K103N HIV-1 RT mutation above a threshold are associated with virological failure in treatment-naive patients undergoing EFV-containing antiretroviral treatment. Antivir Ther 14: 843.
54. Goodman DD, Zhou Y, Marget NA, McColl DJ, Zhong L, et al. (2011) Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 25: 325–333.
55. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356: 135–147.
56. Jourdain G, Wagner TA, Ngo-Giang-Huong N, Sirirungsi W, Klinbuayaem V, et al. (2010) Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis 50: 1397–1404.
57. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR (2007) Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods 146: 136–146.
58. Halvorsen EK, Ailworth GM, Balle P, Beck IA, Bolz VF, et al. (2006) Blinded multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 44: 2612–2614.
59. Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, et al. (2007) Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods 4: 123–125.
60. Beck I, Deng W, Hall R, Payant R, Bumgarner R, et al. Quantification and dynamics of HIV-1 drug resistant mutants in women and in infants exposed to maternal zidovudine and single-dose NVP by pyrosequencing and oligonucleotide ligation assay; 2011 July 17–20; Rome, Italy.
61. Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483–489.
62. Varghese V, Wang E, Babrzadeh F, Bachmann MH, Shahriar R, et al. (2010) Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS One 5: e10992.
63. Beck IA, Croswell C, Kitoor R, Bredell H, Machaba M, et al. (2008) Optimization of the Oligonucleotide Ligation Assay, a Rapid and Inexpensive Test for Detection of HIV-1 Drug Resistance Mutations, for Non-North American Variants. J Acquir Immune Defic Syndr 48: 418–427.